Australian Market Community

Mader Group is a specialist maintenance and technical services provider to mining and heavy industry, best characterised as a supplier of high-skill, outsourced maintenance labour for critical mining and industrial equipment. Over recent years, the company has been a consistent performer, delivering return on equity of around 30% over the past four years.Read more

Harvey Norman has long been a staple of Australian retail, operating across furniture, white goods and consumer electronics, and has traditionally been viewed as a slower-growth, blue-chip stock. While the company does maintain an online presence, its large, iconic physical stores remain central to its strategy.Read more

Credit Corp Group Limited ASX: CCP Market Cap: AU$923.0m Weighted Average Number of Shares: 80.37m The Business CCP’s main business is acquiring portfolios of bad debts from financial institutions and collecting on them for profit. As the original lenders write off these debts, the portfolios are generally bought at a discount.Read more

By Jonathan Goedhart Written 16:19, 02 Dec 2025 AEDT IDAHO / SYDNEY — Resolution Minerals (ASX:RML) appears well-positioned to benefit from sweeping U.S. mining reforms advancing through Congress, as the company continues to deliver strong results from its Horse Heaven gold–antimony district in Idaho. The proposed legislation, H.R. 4090 — the Critical Mineral Dominance Act — aims to fast-track domestic hard-rock mining by accelerating approvals, expanding access to Federal land and prioritising developments containing strategic minerals such as antimony and tungsten.Read more

Catalysts What are the underlying business or industry changes driving this perspective? Data Center and AI-Driven Copper Demand: Beyond general electrification, the explosive growth of Artificial Intelligence (AI) data centers is creating a new, capital-intensive source of demand for copper.Read more

Family Law, Criminal Law, Contested Wills and Estate Legal Services. July 2023 Chris Mcfadden took over as CEO and began the implementation of a People First Culture allowing them to improve hiring prospects and employee retention which is incredibly important in the current competency crisis.Read more

Imagine a retailer sitting on a mountain of cash that covers nearly 40% of its entire stock market value, with zero debt, and a dividend yield that dwarfs most of the market. Now, what if that same company, after being left for dead by investors, just posted a sharp rebound in sales and has a new CEO at the helm who is successfully reigniting the brand?Read more

At a current market capitalisation of approximately A$150 million , Paradigm Biopharmaceuticals appears materially undervalued when compared to peers advancing osteoarthritis (OA) disease modifying therapies, particularly Kolon TissueGene , whose valuation translates to ~A$55 per share at today’s exchange rates. Kolon’s lead asset, TG‑C , is a gene modified, allogeneic cell therapy combining irradiated chondrocytes with HEK293 cells overexpressing TGF‑β1, and is currently in a global Phase 3 trial for knee OA.Read more

Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.Read more